ASH 2015 | Multiple myeloma clinical trials: What’s hot at ASH 2015?

Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, summarises data on the management of patients with multiple myeloma that were presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition.

Highlights include IFM/DFCI 2009, a phase 3 trial of autologous transplantation for multiple myeloma; Tourmaline-MM1, a phase 3 trial of ixazomib in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma; an update on Eloquent-2, a phase 3 trial of elotuzumab in combination with lenalidomide/dexamethasone for relapsed/refractory multiple myeloma; GEN505, a trial of daratumumab monotherapy in heavily pretreated relapsed or refractory multiple myeloma; subgroup analysis from Aspire, a phase 3 trial of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed multiple myeloma based on cytogenetic risk status; and subgroup analysis from Endeavor, a phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma based on cytogenetic risk status.